Opportunity Information: Apply for RFA NS 12 002
Apply for RFA NS 12 002
- The National Institutes of Health in the education environment health income security and social services sector is offering a public funding opportunity titled "NIH Blueprint for Neuroscience Research Grand Challenge Developing Novel Drugs for Disorders of the Nervous System (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.121 Oral Diseases and Disorders Research 93.173 Research Related to Deafness and Communication Disorders 93.213 Research and Training in Complementary and Integrative Health 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.361 Nursing Research 93.389 National Center for Research Resources 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.859 Biomedical Research and Research Training 93.865 Child Health and Human Development Extramural Research 93.866 Aging Research 93.867 Vision Research.
- This funding opportunity was created on Mar 16, 2011 and posted on Mar 15, 2011.
- Applicants must submit their applications by Dec 15, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $125,000.00 in funding.
- Eligible applicants include: County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments City or township governments Private institutions of higher education State governments Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign (non U.S.) components of U.S. Organizations are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH Blueprint for Neuroscience Research Grand Challenge, Developing Novel Drugs for Disorders of the Nervous System (U01) (Funding Opportunity Number RFA-NS-12-002), was a discretionary NIH funding opportunity designed to help investigators move promising small-molecule neurotherapeutics closer to the clinic by plugging them into a "virtual pharma" development network. The central idea is that many academic and early-stage groups can identify interesting compounds and build disease-relevant assays, but they often lack the specialized, expensive infrastructure needed to optimize a molecule, complete IND-enabling studies, and run early human testing. This program aimed to close that gap by combining direct grant funding with coordinated access to professional drug development services that typical academic labs do not have.
The award uses the U01 cooperative agreement mechanism, which signals that NIH expects substantial programmatic involvement and active collaboration rather than a hands-off grant. Under this structure, awardees would conduct biological testing of compound analogs in their own laboratories using their disease assays and models, while also working closely with the NIH-supported development network. In practical terms, investigators bring a starting point (a small-molecule lead and a disease-relevant experimental system) and the program helps advance that lead through the development pipeline using both the investigator's biology capabilities and the network's development expertise.
A major feature of the opportunity is the combination of two types of support. First, applicants could receive funding to support the biology work required to evaluate compound analogs in relevant assays and models. Second, and just as important, awardees could receive no-cost access to contracted drug development services. These services include medicinal chemistry optimization (to improve potency, selectivity, and drug-like properties), IND-directed pharmacology and toxicology (the kinds of studies typically required to support an Investigational New Drug application), and Phase I clinical testing. The presence of Phase I support indicates the program was oriented toward real translational advancement, not just early discovery, with the expectation that successful projects could progress toward first-in-human evaluation.
The opportunity was targeted to researchers who already had (1) small-molecule compounds that look promising for treating nervous system and psychiatric disorders and (2) disease assays or models capable of testing those compounds, but where the compounds were not yet ready for clinical testing. In other words, it was meant for projects sitting in the common "translational valley" between an intriguing lead and a clinically viable candidate, where medicinal chemistry refinement, safety profiling, and development planning are often the major bottlenecks.
From an eligibility standpoint, the FOA was broadly open to a wide range of organizations, including public and private institutions of higher education, nonprofits (including 501(c)(3) organizations), for-profit organizations (other than small businesses, though small businesses were also listed as eligible), state and local governments, tribal governments and organizations, school districts, special district governments, housing authorities, and other entities as allowed under NIH rules. It also allowed non-U.S. (foreign) organizations and foreign components of U.S. organizations, and it explicitly included categories such as HBCUs, Hispanic-serving institutions, tribal colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations. The listing of many CFDA numbers reflects that the program aligned with multiple NIH mission areas that touch neuroscience, mental health, addiction, aging, child health, sensory disorders, and related biomedical research domains.
Administratively, the FOA was posted in mid-March 2011, with an original and current closing date of December 15, 2011, and it was later archived on January 15, 2012. It did not require cost sharing or matching. The posted award ceiling in the source data is $125,000, although the distinguishing value of the program is not only the direct dollars but the attached no-cost development services that can be far more expensive than typical academic project budgets.
Overall, this grant opportunity was structured to function like an accelerator for neurotherapeutics: investigators contribute innovative biology, disease insight, and early chemical matter, while NIH coordinates a development network that can carry a project through medicinal chemistry, IND-enabling studies, and initial clinical evaluation. The end goal is to increase the odds that promising small-molecule treatments for neurological and psychiatric disorders can be translated into real drug candidates that are credible for clinical testing.
Frequently Asked Questions (FAQs)
What is the NIH Blueprint for Neuroscience Research Grand Challenge described here?
It is a discretionary NIH funding opportunity designed to help investigators advance promising small-molecule neurotherapeutics toward clinical testing by connecting them to a coordinated "virtual pharma" drug development network.
What is the official name and funding opportunity number (FOA/FON)?
The opportunity is titled "The NIH Blueprint for Neuroscience Research Grand Challenge, Developing Novel Drugs for Disorders of the Nervous System (U01)" with Funding Opportunity Number RFA-NS-12-002.
What is the primary goal of this program?
The goal is to move promising small-molecule candidates closer to the clinic by addressing common translational bottlenecks such as medicinal chemistry optimization, IND-enabling pharmacology/toxicology, and early human testing, while leveraging the investigator's disease-relevant biology and assays.
What kinds of projects was this opportunity intended to support?
It was intended for projects with small-molecule compounds that appear promising for neurological, nervous system, and psychiatric disorders, where the investigators also have disease-relevant assays or models to test compounds, but the lead compounds are not yet ready for clinical testing.
What stage of drug development was this program focused on?
It focused on the "translational valley" between an intriguing lead compound and a clinically viable candidate, emphasizing medicinal chemistry refinement, safety profiling, and development planning needed to progress toward first-in-human studies.
What does the U01 cooperative agreement mechanism mean for applicants and awardees?
A U01 cooperative agreement indicates substantial NIH programmatic involvement and active collaboration. Rather than a hands-off grant, this structure anticipates that awardees will work closely with NIH and the NIH-supported development network as the project advances.
What work would awardees typically perform in their own labs?
Awardees would conduct biological testing of compound analogs using their own disease assays and models, applying their in-house biology capabilities to evaluate performance as the compounds are optimized and advanced.
What role does the NIH-supported development network play?
The network provides coordinated access to professional drug development capabilities and services that academic or early-stage groups often lack, helping advance a lead through key development steps.
What types of support are provided under this opportunity?
The opportunity combines (1) direct grant funding to support biology work for evaluating compound analogs in relevant assays and models, and (2) no-cost access to contracted drug development services coordinated through the program.
What does "no-cost access to contracted drug development services" include?
The described services include medicinal chemistry optimization, IND-directed pharmacology and toxicology studies, and Phase I clinical testing, provided through contracted resources as part of the program support.
Does this program support medicinal chemistry?
Yes. A core component is medicinal chemistry optimization intended to improve potency, selectivity, and drug-like properties of the small-molecule leads.
Does this opportunity support IND-enabling studies?
Yes. It includes IND-directed pharmacology and toxicology studies that are typically required to support an Investigational New Drug (IND) application.
Does the program support Phase I clinical testing?
Yes. Phase I clinical testing is explicitly included among the contracted services, reflecting an emphasis on real translational advancement toward first-in-human evaluation.
Is the value of this opportunity limited to the direct grant dollars?
No. While a posted award ceiling of $125,000 appears in the source data, the program's distinguishing value also includes access to no-cost development services that can be substantially more expensive than typical academic project budgets.
What kinds of therapeutic modalities are emphasized?
The described focus is on small-molecule neurotherapeutics intended to treat disorders of the nervous system and psychiatric disorders.
Who is this opportunity best suited for?
It is best suited for researchers and groups that already have a promising small-molecule lead and a disease-relevant experimental system (assays/models) but need specialized development infrastructure to optimize the molecule and complete preclinical and early clinical steps.
What types of organizations were eligible to apply?
Eligibility was broadly open to many organization types, including public and private institutions of higher education, nonprofit organizations (including 501(c)(3)), for-profit organizations, small businesses (also listed as eligible), state and local governments, tribal governments and organizations, school districts, special district governments, housing authorities, and other entities allowed under NIH rules.
Were non-U.S. (foreign) organizations eligible?
Yes. The opportunity allowed non-U.S. (foreign) organizations and also permitted foreign components of U.S. organizations.
Did the eligibility language explicitly include certain institution categories (like HBCUs or tribal colleges)?
Yes. It explicitly included categories such as HBCUs, Hispanic-serving institutions, tribal colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations.
Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
When was the FOA posted and when did it close?
The FOA was posted in mid-March 2011. The original and current closing date was December 15, 2011.
When was the opportunity archived?
It was archived on January 15, 2012.
What is the posted award ceiling mentioned in the source information?
The posted award ceiling in the provided source data is $125,000.
Why does the description mention multiple CFDA numbers?
The listing of many CFDA numbers reflects that the program aligned with multiple NIH mission areas related to neuroscience and connected domains such as mental health, addiction, aging, child health, sensory disorders, and related biomedical research.
How does this program function like an "accelerator" for neurotherapeutics?
It is structured so investigators contribute innovative biology, disease insight, and early chemical matter, while NIH coordinates a development network to help carry projects through medicinal chemistry, IND-enabling studies, and initial clinical evaluation to improve the chances of reaching credible clinical testing.
What is the basic collaboration model described for projects under this FOA?
Investigators bring a starting point (a small-molecule lead plus disease-relevant assays/models) and perform biological testing, while working closely with an NIH-supported network that provides development services to advance the lead through the pipeline.
Browse more opportunities from the same category: Education Environment Health Income Security and Social Services
Next opportunity: Office of Elementary and Secondary Education (OESE) Advanced Placement Incentive Program CFDA Number 84.330C
Previous opportunity: Chronicle of Lineage Indicative of Origins (CLIO)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NS 12 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NS 12 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research on Ethical Issues in Biomedical, Social and Behavioral Research (R01) Apply for PA 11 180 Funding Number: PA 11 180 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Research on Ethical Issues in Biomedical, Social, and Behaviora Research (R03) Apply for PA 11 181 Funding Number: PA 11 181 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Research on Ethical Issues in Biomedical, Social, and Behavioral Research (R21) Apply for PA 11 182 Funding Number: PA 11 182 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Independent Scientist Award (Parent K02) Apply for PA 11 191 Funding Number: PA 11 191 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Predictive Multiscale Models for Biomedical, Biological, Behavioral, Environmental and Clinical Research (Interagency U01) Apply for PAR 11 203 Funding Number: PAR 11 203 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Sharing Data and Tools Federation using the BIRN and caBIG Infrastructures (R01) Apply for PAR 07 426 Funding Number: PAR 07 426 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NS 12 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.